研究单位：[1]Haisco Pharmaceutical Group Co., Ltd.[2]Dongguan People's Hospital,Dongguan,Guangdong,China[3]Foshan Fuxing Chancheng Hospital,Foshan,Guangdong,China[4]The First Affiliated Hospital of Jinan University,Guangzhou,Guangdong,China[5]Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou,China[6]Beijing Jishuitan Hospital Guizhou Hospital,Guiyang,Guizhou,China[7]Zunyi University Affiliated Hospital,Zunyi,Guizhou,China[8]Henan Provincial People's Hospital,Zhengzhou,Henan,China[9]People's Hospital of Wuhan University,Wuhan,Hubei,China[10]Wuhan Central Hospital,Wuhan,Hubei,China[11]Xiangya Third Hospital of Central South University,Changsha,Hunan,China[12]The First Affiliated Hospital of South China University,Hengyang,Hunan,China[13]Lianyungang First People's Hospital,Lianyungang,Jiangsu,China[14]Nanjing First Hospital,Nanjing,Jiangsu,China[15]Chengdu Second People's Hospital,Chengdu,Sichuan,China[16]Chengdu Third People's Hospital,Chengdu,Sichuan,China[17]Sichuan Provincial People's Hospital,Chengdu,Sichuan,China[18]Guangyuan First People's Hospital,Guangyuan,Sichuan,China[19]Mianyang Central Hospital,Mianyang,Sichuan,China[20]Yibin Second People's Hospital,Yibin,Sichuan,China[21]The First People's Hospital of Yunnan Province,Kunming,Yunnan,China[22]Sino-Japanese Friendship Hospital,Beijing,China
研究目的：
This study will compare the effect and safety of HSK16149 with placebo on perioperative analgesia in orthopedic surgery, and explore the dosage of HSK16149 capsules for orthopedic analgesia during perioperative period.
